Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

FDA fast-tracks Teva's coeliac disease treatment

Teva gets fast-track status from the FDA for a coeliac disease drug with a mechanism that has proved tough to crack

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac diseaseCandidate demonstrates Teva’s commitment to bringing important new treatment options to underserved patient populations

Breakthrough: FDA Fast-Tracks Novel Celiac Disease Treatment as Teva Advances Phase 2 Trial

FDA expedites TEV-53408 development for 1% of global population affected by celiac disease. Novel IL-15 antibody shows promise in ongoing trials. See latest data.